PuSH - Publikationsserver des Helmholtz Zentrums München

Zeitschriften-Browsing

66 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... ▶▶ ▶▮
Alle Publikationen dieser Seite in den Korb legen
21.
Angenendt, L.* et al.: The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia. Leukemia 33, 2830-2841 (2019)
22.
Lynch, J.R.* et al.: JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis. Leukemia 33, 1400-1410 (2019)
23.
Vrzalikova, K.* et al.: S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells (vol 32, pg 214, 2018). Leukemia 33, 2126-2126 (2019)
24.
Anastasiadou, E.* et al.: Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia 33, 132–147 (2018)
25.
Reiter, K.* et al.: Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia. Leukemia 32, 313-322 (2018)
26.
Schneidt, V.* et al.: Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary CLL ex vivo. Leukemia 33, 88-98 (2018)
27.
Tirado-Gonzalez, I.* et al.: CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC. Leukemia 32, 1048-1051 (2018)
28.
Neuenhahn, M. et al.: Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. Leukemia 31, 2161-2171 (2017)
29.
Vrzalikova, K.* et al.: S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells. Leukemia 32, 214-223 (2017)
30.
Wurster, K.D.* et al.: Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma. Leukemia 31, 602-613 (2017)
31.
Dutta, S. et al.: The target cell of transformation is distinct from the leukemia stem cell in murine CALM/AF10 leukemia models. Leukemia 30, 1166-1176 (2016)
32.
Krupka, C. et al.: Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3-BiTE antibody construct AMG 330: Reversing a T-cell induced immune escape mechanism. Leukemia 30, 484-491 (2016)
33.
Spinner, S.* et al.: Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance. Leukemia 30, 1520-1530 (2016)
34.
Alsadeq, A.* et al.: Effects of p38α/β inhibition on Acute Lymphoblastic Leukemia (ALL) proliferation and survival in vivo. Leukemia 29, 2307-2316 (2015)
35.
Köhnke, T.* et al.: Early assessment of minimal residual disease in aml by flow cytometry during aplasia identifies patients at increased risk of relapse. Leukemia 29, 377-386 (2015)
36.
Sandhöfer, N. et al.: Dual PI3K/mTOR inhibition shows antileukemic activity in MLL rearranged acute myeloid leukemia. Leukemia 29, 828-838 (2015)
37.
Klar, R.* et al.: Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands in myeloid leukemia cells by TCR-transgenic T cells. Leukemia 28, 2355-2366 (2014)
38.
Stadler, C.R. et al.: The leukemogenicity of Hoxa9 depends on alternative splicing. Leukemia 28, 1838-1843 (2014)
39.
Schnittger, S.* et al.: ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 27, 82-91 (2013)
40.
Finnon, R.* et al.: Flt3-ITD mutations in a mouse model of radiation-induced acute myeloid leukaemia. Leukemia 26, 1445-1446 (2012)
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... ▶▶ ▶▮